Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS' ORAL SMALL-MOLECULE KRAS G12D INHIBITOR ABSK141 COMPLETED FIRST PATIENT DOSING

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that the first patient has been successfully dosed in the Phase I/II clinical study of ABSK141, an oral, highly potent, and selective small-molecule KRAS G12D inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK141 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 4 March 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics' Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Completed First Patient Dosing

On 4 March 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that the first patient has been successfully dosed in the Phase I/II clinical study of ABSK141, an oral, highly potent, and selective small-molecule KRAS G12D inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations.

KRAS is one of the most common oncogenic driver genes in human cancers, with G12D being the predominant mutation subtype. It is widely present in various solid tumors such as pancreatic ductal adenocarcinoma ("**PDAC**"), colorectal cancer ("**CRC**"), and non-small cell lung cancer ("**NSCLC**"). The G12D mutation induces specific conformational changes in the KRAS protein, which has long been regarded as an "undruggable" target, posing significant challenges to the development of targeted therapies. To date, no targeted therapy for KRAS G12D mutations has been approved worldwide.

This first-patient dosing was completed in an open-label Phase I/II clinical study. The study received Investigational New Drug ("**IND**") approvals from the U.S. Food and Drug Administration ("**US FDA**") and the China National Medical Products Administration ("**China NMPA**") in December 2025.

The successful advancement of the ABSK141 clinical study marks an important milestone for Abbisko Therapeutics in the field of KRAS-targeted therapy, and is expected to potentially provide a transformative treatment option for patients with KRAS G12D-mutated solid tumors.

About ABSK141

ABSK141 is a novel, oral small-molecule KRAS G12D inhibitor independently designed and developed by Abbisko Therapeutics. It binds selectively to the KRAS G12D mutant protein, thereby blocking downstream signaling pathways and inhibiting tumor cell proliferation. Preclinical studies have demonstrated that ABSK141 possesses potential best-in-class oral bioavailability across multiple animal models and exhibits strong anti-tumor activity in various human cancer cell line-derived xenograft ("**CDX**") models, including PDAC and CRC.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.